American Diabetes Association: Evidence-Based Guidelines For Standards Of Care In Diabetes 2025

• Guidance on actions to take during circumstances of medication unavailability, such as medication shortages. 

• Additional guidance on the use of GLP-1 receptor agonists beyond weight loss for heart and kidney health benefits.

• Guidance on continuation of weight management pharmacotherapy beyond reaching weight loss goals.

• Guidance for treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) with moderate or advanced liver fibrosis using a thyroid hormone receptor-beta agonist.

• Emphasis on the use of antibody-based screening for presymptomatic type 1 diabetes in those who have a family history or known genetic risk.

• Guidance on the use of recreational cannabis for type 1 diabetes and those with other forms of diabetes at risk for diabetic ketoacidosis (DKA).

• Key updates highlighting potentially harmful medications in pregnancy and guidance for appropriately modifying the care plan.

• Expanded nutrition guidance to encourage evidence-based eating patterns, including those incorporating plant-based proteins and fiber, that keep nutrient quality, total calories, and metabolic goals in mind.

Reference: https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2025#:~:text=Notable updates to the Standards,unavailability, such as medication shortages.